<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03064243</url>
  </required_header>
  <id_info>
    <org_study_id>Ahead-S301</org_study_id>
    <nct_id>NCT03064243</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Apatinib in STS Patients</brief_title>
  <official_title>Effectiveness and Safety of Apatinib for the Patients With Advanced Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University Affiliated Sixth People’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University Affiliated Sixth People’s Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apatinib is a kind of innovative medicines approved by China Food and Drug
      Administration（CFDA）, which was researched by Jiangsu Hengrui Pharmaceutical Co., Ltd.
      Apatinib is a kinase inhibitor of receptor tyrosine with VEGFR2. The protocol is to explore
      Apatinib for the effectiveness of advanced soft tissue sarcoma and safety.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 months PFS rate</measure>
    <time_frame>From baseline to 6 months</time_frame>
    <description>Analyse PFS rate at 6 months</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>apatinib group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>apatinib 500mg po qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apatinib</intervention_name>
    <description>apatinib 500mg po. qd.</description>
    <arm_group_label>apatinib group</arm_group_label>
    <other_name>apatinib mesylate tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent.

          -  Histologically proven advanced soft tissue sarcoma, At least one measurable lesion.
             Including: Synovial sarcoma, leiomyosarcoma, Alveolar soft part sarcoma,
             Undifferentiated pleomorphic sarcoma / malignant fibrous histiocytoma, Liposarcoma,
             Fibrosarcoma, Clear cell sarcoma, Epithelioid sarcoma, Angiosarcoma, Spindle cell
             sarcoma, rhabdomyosarcoma treated by chemotherapy, Ewing's sarcoma of soft
             tissue/Primitive neuroectodermal tumor. Excluding: Malignant peripheral nerve sheath
             tumor, chondrosarcoma, Dermatofibrosarcoma protuberans, Gastrointestinal stromal
             tumor, Inflammatory myofibroblastic sarcoma, Malignant mesothelioma.

          -  Must have evidence of unresectable residual disease.

          -  In the last 6 months, at least one chemotherapy regimen (including anthracyclines) was
             used in patients who failed or were unable to tolerate treatment.

          -  ECOG ps≤2.

          -  Life expectancy: more than 3 months.

          -  Prior aptinib less than 2 weeks and at least 1 month since prior aptinib；at least 1
             month since prior inhibitor of mTOR or EGFR pathway.

          -  Not pregnant or nursing；Fertile patients must use effective contraception.

          -  Hematopoietic

               -  HB≥90g/L

               -  Absolute neutrophil count ≥ 1,500/mm^3

               -  Platelet count ≥ 80,000/mm^3

        Exclusion Criteria:

          -  Uncontrollable hypertension;

          -  Has influence of oral drugs;

          -  Patients with high risk of gastrointestinal blooding;

          -  INR&gt;1.5×ULN，APTT&gt;1.5×ULN;

          -  Allergic to any ingredient of this product;

          -  Less than 1 month since last major surgery;

          -  Brain metastases;

          -  With the second cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2017</study_first_submitted>
  <study_first_submitted_qc>February 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2017</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University Affiliated Sixth People’s Hospital</investigator_affiliation>
    <investigator_full_name>Yang Yao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

